Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Iruplinalkib + QL1203 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Iruplinalkib | WX0593|WX 0593|FL 006|FL-006|FL006|WX-0593 | ALK Inhibitor 33 EGFR Inhibitor (Pan) 63 ROS1 Inhibitor 23 | Iruplinalkib (WX-0593) inhibits ALK and ROS1, with additional activity against EGFR mutations, which may lead to decreased tumor growth (PMID: 35087031; Cancer Res 2018;78(13 Suppl):Abstract nr 4794). | |
| QL1203 | QL-1203|QL 1203 | EGFR Antibody 72 | QL1203 is a monoclonal antibody directed against EGFR, which potentially inhibits tumor growth (PMID: 35845484). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|